Author: NSV
Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. “We believe that 2025 will be
Read More
Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI
Sagence AI™ has emerged from stealth unveiling a groundbreaking advanced analog in-memory compute architecture that directly addresses the untenable power/performance/price and environmental sustainability conundrum facing AI inferencing. Driven by its industry-first architectural innovations using analog technology, Sagence AI makes possible multiple orders of magnitude improvement in energy efficiency and cost
Read MoreVentyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative
Read More
Achronix releases groundbreaking Speedster AC7t800 Mid-Range FPGA, driving innovation in AI/ML, 5G/6G and Data Center Applications
Achronix Semiconductor Corporation, a leader in FPGA-based hardware accelerator devices and high-performance eFPGA IP, has announced the availability and shipment of AC7t800 FPGA, designed to address the rapidly growing needs of data-centric applications such as generative AI, DPUs and SmartNICs. With samples available today and units already shipped to customers,
Read MoreVentyx Biosciences announces $27 million strategic investment from Sanofi
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of
Read More
PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program
PlanetiQ, a leading innovator of global atmospheric observing systems, has been awarded a Delivery Order (DO-4) contract valued at over $6.5M to supply the National Oceanic and Atmospheric Administration (NOAA) with their proprietary radio occultation (RO) data for a period of one year beginning September 18, 2024. “In addition to
Read MoreVentyx Biosciences announces initiation of dosing in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s
Read More
Vascular Therapies completes enrollment in the ACCESS 2 study, a Phase III multinational randomized clinical trial of the Sirolimus Eluting Collagen Implant (Sirogen™) for the surgical creation of arteriovenous fistula for hemodialysis vascular access
Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, has announced completion of enrollment in the ACCESS 2 trial, a Phase III prospective randomized, multicenter clinical study of Sirogen™ for the surgical creation of arteriovenous (AV) fistula in patients requiring hemodialysis vascular access.
Read MoreVentyx Biosciences announces results from the Phase 2 trial of VTX958 in participants with moderately to severely active Crohn’s disease
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of its allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active
Read More
Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters
Phase Four, a leading provider of next generation electric propulsion solutions for satellites, proudly announces the signing of a strategic cooperation agreement with Redwire Space (Redwire). This partnership aims to build and deliver Hall Effect Thrusters (HETs) to both government and commercial markets, enhancing the company's capabilities and expanding our
Read MorePrimemas selects Achronix embedded FPGA technology for System-on-Chip (SoC) Hub Chiplet platform
Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Primemas, a fabless semiconductor company developing an innovative SoC Hub Chiplet (Hublet) platform using chiplet technology, has announced a collaboration to bring FPGA programmability to the Primemas suite of products. Primemas chose the Speedcore™ eFPGA IP
Read MoreVentyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models. “We are excited by these
Read More